A Phase I Study of the Pharmacokinetics, Safety and Tolerability of a Novel Tocopheryl Phosphate Mixture/Oxymorphone Transdermal Patch System

References

• Chou R , FanciulloGJ , FinePGet al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain . J. Pain10 ( 2 ), 113 – 30 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Fields HL . The doctor’s dilemma: opiate analgesics and chronic pain . Neuron69 ( 4 ), 591 – 594 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Martin C , BaerdemaekerAD , PoelaertJet al. Controlled-release of opioids for improved pain management . Mater. Today19 ( 9 ), 491 – 502 ( 2016 ).
   Web of Science ®Google Scholar
• Khansari M , SohrabiM , ZamaniF . The usage of opioids and their adverse effects in gastrointestinal practice: a review . Middle East J. Dig. Dis.5 ( 1 ), 5 – 16 ( 2013 ).
   PubMedGoogle Scholar
• Moorman-Li R , MotyckaCA , IngeLDet al. A review of abuse-deterrent opioids for chronic nonmalignant pain . PT37 ( 7 ), 412 – 418 ( 2012 ).
   PubMedGoogle Scholar
• Hahn KL . Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs . Am. Health Drug Benefits4 ( 2 ), 107 – 114 ( 2011 ).
   PubMedGoogle Scholar
• FDA . www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM492172.pdf .
   Google Scholar
• Brennan MJ . Update on prescription extended-release opioids and appropriate patient selection . J. Multidiscip. Healthc.6 , 265 – 280 ( 2013 ).
   PubMedGoogle Scholar
• Margetts L , SawyerR . Transdermal drug delivery: principles and opioid therapy, continuing education in anaesthesia . Crit. Care Pain7 ( 5 ), 171 – 176 ( 2007 ).
   Google Scholar
• Kaiko RF . The effect of food intake on the pharmacokinetics of sustained-release morphine sulfate capsules . Clin. Ther.19 ( 2 ), 296 – 303 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Conaghan PG , O’BrienCM , WilsonM , SchofieldJP . Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial . Osteoarthritis Cartilage19 , 930 – 938 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bajaj S , WhitemanA , BrandnerB . Transdermal drug delivery in pain management . Contin. Educ. Anaesth. Crit. Care Pain11 ( 2 ), 39 – 43 ( 2011 ).
   Google Scholar
• Khanna IK , PillarisettiS . Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain . J. Pain Res.8 , 859 – 70 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Schmid-Grendelmeier P , PokornyR , GasserU , RicharzU . A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers . Curr. Med. Res. Opin.22 , 501 – 509 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Serpell M , TripathiS , ScherzingerS . Assessment of transdermal buprenorphine patches for the treatment of chronic pain in a UK observational study . Patient9 ( 1 ), 35 – 46 ( 2016 ).
   PubMedGoogle Scholar
• BuTrans patches – Summary of Product Characteristics .http://www.medicines.org.uk/emc/medicine/16787
   Google Scholar
• Harris SC , MorganrothJ , RipaSR , ThornMD , ColucciS . Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive and placebo-controlled trials . Postgrad. Med.129 ( 1 ), 69 – 80 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Friesen KJ , WoelkC , BugdenS . Safety of fentanyl initiation according to past opioid exposure among patients newly prescribed fentanyl patches . CMAJ188 ( 9 ), 648 – 653 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Gavin PD , SimonLS , SchlagheckT , SmithAJ , ShakibS . Pharmacokinetics, safety and tolerability of a novel TPM/oxycodone transdermal patch system: a Phase I study . Pain Manag. doi:10.2217/pmt-2016-0068 ( 2017 ) ( Epub ahead of print ).
   Google Scholar
• Gavin PD , El-TamimyM , KeahHH , BoydBJ . Tocopheryl phosphate mixture (TPM) as a novel lipid-based transdermal drug delivery carrier: formulation and evaluation . Drug Deliv. Transl. Res.7 ( 1 ), 53 – 65 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Smith HS . Clinical pharmacology of oxymorphone . Pain Med.10 ( s1 ), S3 – S10 ( 2009 ).
   Google Scholar
• Trescot AM , DattaS , LeeM , HansenH . Opioid pharmacology . Pain Physician11 ( Suppl. 2 ), S133 – S153 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• OPANA® . (Oxymorphone hydrochloride) tablets [prescribing information] . Endo Pharamceuticals, Inc. , PA, USA ( 2012 ). www.accessdata.fda.gov/drugsatfda_docs/label/2012/021611s007lbl.pdf .
   Google Scholar
• OPANA® . ER (oxymorphone hydrochloride) Extended-Release tablets [prescribing information] . Endo Pharamceuticals Inc. , PA, USA ( 2016 ). www.endo.com/File%20Library/Products/Prescribing%20Information/OpanaER_prescribing_information_newformulation.html .
   Google Scholar
• Medscape Medical News . www.medscape.com/viewarticle/877352 .
   Google Scholar
• Likar R . Transdermal buprenorphine in the management of persistent pain – safety aspects . Ther. Clin. Risk Manag.2 ( 1 ), 115 – 125 ( 2006 ).
   PubMedGoogle Scholar
• Peng PW , SandlerAN . A review of the use of fentanyl analgesia in the management of acute pain in adults . Anesthesiology90 ( 2 ), 576 – 599 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Gavin P , TremperL , SmithA , WilliamsG , BrookerC . Transdermal oxycodone patch for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled trial . Pain Manag. doi:10.2217/pmt-2016-0067 ( 2017 ) ( Epub ahead of print ).
   Google Scholar
• Lynn BW , YeW , CotsellB . The actions of capsaicin applied topically to the skin of the rat on C-fibre afferents, antidromic vasodilatation and substance P levels . Br. J. Pharmacol.107 ( 2 ), 400 – 406 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Jones VM , MooreKA , PetersonDM . Capsaicin 8% topical patch (Qutenza) – a review of the evidence . J. Pain Palliat. Care Pharmacother.25 ( 1 ), 32 – 41 ( 2011 ).
   PubMedGoogle Scholar
• Likar R , LorenzV , Korak-LeiterM , KagerI , SittlR . Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison . Clin. Ther.29 ( 8 ), 1591 – 1606 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Perez-Perez L , CabanillasM , LoureiroMet al. Allergic contact dermatitis due to transdermal buprenorphine . Contact Dermatitis58 ( 5 ), 310 – 312 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• US FDA . www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm .
   Google Scholar
• Medline Plus . http://medlineplus.gov/news/fullstory_166423.html .
   Google Scholar